Ashland (ASH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended March 2025, Ashland (ASH) reported revenue of $479 million, down 16.7% over the same period last year. EPS came in at $0.99, compared to $1.27 in the year-ago quarter.

The reported revenue represents a surprise of -5.86% over the Zacks Consensus Estimate of $508.82 million. With the consensus EPS estimate being $1.10, the EPS surprise was -10.00%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Ashland performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Life Sciences: $172 million versus $177.02 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -22.5% change.
• Revenue- Intermediates: $37 million versus $36.38 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -7.5% change.
• Revenue- Specialty Additives: $134 million compared to the $141.10 million average estimate based on two analysts. The reported number represents a change of -14.7% year over year.
• Revenue- Personal Care: $146 million versus the two-analyst average estimate of $162.83 million. The reported number represents a year-over-year change of -13.6%.
• Adjusted EBITDA- Life Science: $56 million versus $53.75 million estimated by two analysts on average.
• Adjusted EBITDA- Intermediates: $2 million versus the two-analyst average estimate of $6.15 million.
• Adjusted EBITDA- Specialty Additives: $26 million compared to the $25.22 million average estimate based on two analysts.
• Adjusted EBITDA- Personal Care: $44 million versus $46.25 million estimated by two analysts on average.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research